Alentis Therapeutics Ag
Clinical trials sponsored by Alentis Therapeutics Ag, explained in plain language.
-
New drug ALE.P02 targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus that have spread or cannot be removed. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 170 adult…
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New Antibody-Drug conjugate takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New antibody aims to shield kidneys from autoimmune attack
Disease control Recruiting nowThis Phase 2 trial tests whether adding ALE.F02 to standard therapy can protect kidney function in people with ANCA-associated vasculitis, an autoimmune disease that attacks small blood vessels, often damaging the kidneys. About 80 participants will receive either a low, high, or…
Phase: PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC